All Stories

  1. What’s new in heart failure? February 2026

    Article • European Journal of Heart Failure, March 2026, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  2. Rethinking decongestion in HFpEF: when less diuretic means more disease modification

    Article • European Journal of Heart Failure, March 2026, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  3. Do we need exercise echocardiography to diagnose HFpEF? Not at all

    Article • European Journal of Heart Failure, February 2026, Oxford University Press (OUP)

    Dr Matthew M Y Lee, Dr Pierpaolo Pellicori, Professor John GF Cleland

  4. Implementation of guideline-directed medical therapy in patients with heart failure and obesity: European Journal of Heart Failure expert consensus document

    Article • European Journal of Heart Failure, February 2026, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  5. Abstract 4361884: Improvement in Echocardiographic Measures of Diastolic Function Reflects Improved Exercise Performance in Obstructive Hypertrophic Cardiomyopathy: Insights From the SEQUOIA-HCM Trial

    Article • Circulation, November 2025, Wolters Kluwer Health

    Dr Matthew M Y Lee

  6. Abstract 4370461: Aficamten is safe and effective in oHCM with comorbidities obesity, hypertension, and diabetes: a SEQUOIA-HCM sub-study

    Article • Circulation, November 2025, Wolters Kluwer Health

    Dr Matthew M Y Lee

  7. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial

    Article • Circulation, October 2025, Wolters Kluwer Health

    Dr Matthew M Y Lee

  8. Efficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: Systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trials

    Article • Progress in Cardiovascular Diseases, October 2025, Elsevier

    Dr Matthew M Y Lee

  9. What's new in heart failure? October 2025

    Article • European Journal of Heart Failure, October 2025, Wiley

    Dr Matthew M Y Lee

  10. Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials

    Article • BMJ Open, September 2025, BMJ

    Dr Matthew M Y Lee

  11. Response to Comment on Lee et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without T...

    Article • Diabetes Care, August 2025, American Diabetes Association

    Dr Matthew M Y Lee

  12. What's new in heart failure? August 2025

    Article • European Journal of Heart Failure, August 2025, Wiley

    Dr Matthew M Y Lee

  13. Heart failure and obesity: novel insights leading to new treatment paradigms

    Article • Nature Reviews Cardiology, July 2025, Springer Science + Business Media

    Dr Matthew M Y Lee

  14. Artificial intelligence fully automated analysis of handheld echocardiography in real‐world patients with suspected heart failure

    Article • European Journal of Heart Failure, July 2025, Wiley

    Dr Matthew M Y Lee

  15. Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects

    Article • The Journal of Clinical Pharmacology, July 2025, Wiley

    Dr Matthew M Y Lee

  16. Incretin‐based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta‐analysis of randomized controlled trials

    Article • Diabetes Obesity and Metabolism, June 2025, Wiley

    Dr Matthew M Y Lee

  17. What's new in heart failure? June 2025

    Article • European Journal of Heart Failure, June 2025, Wiley

    Dr Matthew M Y Lee

  18. The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4

    Article • Circulation, May 2025, Wolters Kluwer Health

    Dr Matthew M Y Lee

  19. Peak Oxygen Uptake Vs Ventilatory Efficiency—In Reply

    Article • JAMA Cardiology, May 2025, American Medical Association (AMA)

    Dr Matthew M Y Lee

  20. The intersection of obesity and acute heart failure: cardiac structure and function and congestion across BMI categories

    Article • European Heart Journal Acute Cardiovascular Care, April 2025, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  21. Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions

    Article • The Lancet Diabetes & Endocrinology, April 2025, Elsevier

    Dr Matthew M Y Lee

  22. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials

    Article • Diabetes Care, March 2025, American Diabetes Association

    Dr Matthew M Y Lee

  23. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian Versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations With or Without Type 2 Diabetes and/or Overweight o...

    Article • Diabetes Care, February 2025, American Diabetes Association

    Dr Matthew M Y Lee

  24. Cardiovascular magnetic resonance‐estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction and dysglycaemia (SUGAR‐DM‐

    Article • European Journal of Heart Failure, January 2025, Wiley

    Dr Matthew M Y Lee

  25. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

    Article • The Lancet Diabetes & Endocrinology, January 2025, Elsevier

    Dr Matthew M Y Lee

  26. Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction (EMPRESS‐MI)

    Article • European Journal of Heart Failure, December 2024, Wiley

    Dr Matthew M Y Lee

  27. What's new in heart failure? December 2024

    Article • European Journal of Heart Failure, December 2024, Wiley

    Dr Matthew M Y Lee

  28. Subcutaneous furosemide in heart failure: a systematic review

    Article • European Heart Journal - Cardiovascular Pharmacotherapy, November 2024, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  29. Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy

    Article • Journal of the American College of Cardiology, November 2024, Elsevier

    Dr Matthew M Y Lee

  30. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy

    Article • Journal of the American College of Cardiology, November 2024, Elsevier

    Dr Matthew M Y Lee

  31. Aficamten and Cardiopulmonary Exercise Test Performance

    Article • JAMA Cardiology, November 2024, American Medical Association (AMA)

    Dr Matthew M Y Lee

  32. What's new in heart failure? October 2024

    Article • European Journal of Heart Failure, October 2024, Wiley

    Dr Matthew M Y Lee

  33. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial

    Article • European Heart Journal, September 2024, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  34. Reverse cardiac remodelling: VICTORIA for inflammation and cardiac metabolism

    Article • European Journal of Heart Failure, August 2024, Wiley

    Dr Matthew M Y Lee

  35. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM

    Article • Journal of the American Heart Association, August 2024, Wolters Kluwer Health

    Dr Matthew M Y Lee

  36. Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic – insights from the IRONMAN trial

    Article • European Journal of Heart Failure, July 2024, Wiley

    Dr Matthew M Y Lee

  37. Abstract

    Article • European Journal of Heart Failure, July 2024, Wiley

    Dr Matthew M Y Lee, Dr Anthony D Dimarco

  38. Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure

    Article • International Journal of Cardiology, July 2024, Elsevier

    Dr Matthew M Y Lee

  39. What's new in heart failure? June–July 2024

    Article • European Journal of Heart Failure, June 2024, Wiley

    Dr Matthew M Y Lee

  40. Revisiting Race and the Benefit of RAS Blockade in Heart Failure

    Article • JAMA, June 2024, American Medical Association (AMA)

    Dr Matthew M Y Lee

  41. What's new in heart failure? May–June 2024

    Article • European Journal of Heart Failure, June 2024, Wiley

    Dr Matthew M Y Lee

  42. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, May 2024, New England Journal of Medicine (NEJM/MMS)

    Dr Matthew M Y Lee

  43. 137 Efficacy of intravenous ferric derisomaltose in hospitalised and outpatient settings: insights from ironman trial

    Article • May 2024, BMJ

    Dr Matthew M Y Lee

  44. What the SELECT trial of semaglutide means for clinicians

    Article • Nature Reports Stem Cells, May 2024, Springer Science + Business Media

    Dr Matthew M Y Lee

  45. Measuring congestion with a non‐invasive monitoring device in heart failure and haemodialysis: CONGEST‐HF

    Article • European Journal of Heart Failure, May 2024, Wiley

    Dr Matthew M Y Lee

  46. Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS‐MI): rationale and design

    Article • ESC Heart Failure, May 2024, Wiley

    Dr Matthew M Y Lee

  47. Body mass index and cardiorenal outcomes in the EMPEROR‐Preserved trial: Principal findings and meta‐analysis with the DELIVER trial

    Article • European Journal of Heart Failure, April 2024, Wiley

    Dr Matthew M Y Lee

  48. Heart failure with preserved ejection fraction: everything the clinician needs to know

    Article • The Lancet, March 2024, Elsevier

    Dr Matthew M Y Lee

  49. Advances in Multi-Modality Imaging in Hypertrophic Cardiomyopathy

    Article • Journal of Clinical Medicine, February 2024, MDPI AG

    Dr Matthew M Y Lee

  50. Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy

    Article • JACC Heart Failure, January 2024, Elsevier

    Dr Matthew M Y Lee

  51. EPidemiology Of Cardiogenic sHock in Scotland (EPOCHS): A multicentre, prospective observational study of the prevalence, management and outcomes of cardiogenic shock in Scotland

    Article • Journal of the Intensive Care Society, December 2023, SAGE Publications

    Dr Matthew M Y Lee

  52. Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?

    Article • Current Heart Failure Reports, December 2023, Springer Science + Business Media

    Dr Matthew M Y Lee

  53. A case report of myocardial infarction in a young transgender man with testosterone therapy: raising awareness on healthcare issues in the transgender community and a call for further research

    Article • European Heart Journal - Case Reports, December 2023, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  54. Correction to: Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?

    Article • Current Heart Failure Reports, December 2023, Springer Science + Business Media

    Dr Matthew M Y Lee

  55. Association of CA-125 with markers of congestion, and effect of empagliflozin on CA-125 in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)

    Article • European Heart Journal, November 2023, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  56. Effect of empagliflozin on CMR-estimated pulmonary capillary wedge pressure in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)

    Article • European Heart Journal, November 2023, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  57. Predicting heart failure readmission and all-cause mortality in patients with acute heart failure: a simple predischarge risk score

    Article • European Heart Journal, November 2023, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  58. Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?

    Article • Current Heart Failure Reports, October 2023, Springer Science + Business Media

    Dr Matthew M Y Lee

  59. Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials

    Article • European Heart Journal - Cardiovascular Pharmacotherapy, September 2023, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  60. Influenza vaccination: Simple, safe, and effective for patients with ischaemic heart disease and heart failure

    Article • European Journal of Heart Failure, August 2023, Wiley

    Dr Matthew M Y Lee

  61. A review of current key guidelines for managing high‐risk patients with diabetes and heart failure and future prospects

    Article • Diabetes Obesity and Metabolism, May 2023, Wiley

    Dr Matthew M Y Lee

  62. Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics

    Article • European Heart Journal, May 2023, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  63. Lack of Benefit of Renin-Angiotensin System Inhibitors in COVID-19

    Article • JAMA, April 2023, American Medical Association (AMA)

    Dr Matthew M Y Lee

  64. Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis

    Article • Heart, December 2022, BMJ

    Dr Matthew M Y Lee

  65. Health‐related quality of life in acute heart failure: association between patient‐reported symptoms and markers of congestion

    Article • European Journal of Heart Failure, October 2022, Wiley

    Dr Matthew M Y Lee

  66. Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)

    Article • Circulation, July 2022, Wolters Kluwer Health

    Dr Matthew M Y Lee

  67. 70 Assessing the impact of the covid-19 pandemic on rapid access chest pain clinics: a retrospective audit in glasgow

    Article • June 2022, BMJ

    Dr Matthew M Y Lee

  68. Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial

    Article • Diabetes & Metabolic Syndrome Clinical Research & Reviews, January 2022, Elsevier

    Dr Matthew M Y Lee

  69. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

    Article • The Lancet Diabetes & Endocrinology, October 2021, Elsevier

    Dr Matthew M Y Lee

  70. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction

    Article • Circulation, July 2021, Wolters Kluwer Health

    Dr Matthew M Y Lee

  71. Response by Lee et al to Letter Regarding Article, “Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)”

    Article • Circulation, July 2021, Wolters Kluwer Health

    Dr Matthew M Y Lee

  72. Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size

    Article • Cardiovascular Research, June 2021, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  73. Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes

    Article • Diabetes Care, March 2021, American Diabetes Association

    Dr Matthew M Y Lee

  74. Sex differences in congestive markers in patients hospitalized for acute heart failure

    Article • ESC Heart Failure, March 2021, Wiley

    Dr Matthew M Y Lee

  75. Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations

    Article • Open Heart, February 2021, BMJ

    Dr Matthew M Y Lee

  76. SGLT2 inhibitors ‐ the first successful treatment for HFpEF?

    Article • European Journal of Heart Failure, January 2021, Wiley

    Dr Matthew M Y Lee

  77. Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis

    Article • European Heart Journal - Cardiovascular Pharmacotherapy, December 2020, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  78. EMPEROR-REDUCED reigns while EMPERIAL whimpers

    Article • European Heart Journal, December 2020, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  79. Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association’s Scientific Sessions 2020 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2020

    Article • Circulation, December 2020, Wolters Kluwer Health

    Dr Matthew M Y Lee

  80. Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)

    Article • Circulation, November 2020, Wolters Kluwer Health

    Dr Matthew M Y Lee

  81. Displacement Encoding With Stimulated Echoes Enables the Identification of Infarct Transmurality Early Postmyocardial Infarction

    Article • Journal of Magnetic Resonance Imaging, July 2020, Wiley

    Dr Matthew M Y Lee

  82. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?

    Article • Arteriosclerosis Thrombosis and Vascular Biology, January 2020, Wolters Kluwer Health

    Dr Matthew M Y Lee

  83. Comparing the interobserver reproducibility of different regions of interest on multi-parametric renal magnetic resonance imaging in healthy volunteers, patients with heart failure and renal transplant recipients

    Article • Magnetic Resonance Materials in Physics Biology and Medicine, December 2019, Springer Science + Business Media

    Dr Matthew M Y Lee

  84. Report from the Annual Conference of the British Society of Echocardiography, November 2017, Edinburgh International Conference Centre, Edinburgh

    Article • Echo Research and Practice, December 2019, Bioscientifica

    Dr Matthew M Y Lee

  85. Lung Ultrasound in Acute Heart Failure

    Article • JACC Heart Failure, October 2019, Elsevier

    Dr Matthew M Y Lee

  86. Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome

    Article • Circulation Cardiovascular Interventions, August 2019, Wolters Kluwer Health

    Dr Matthew M Y Lee

  87. Statins in the Prevention and Treatment of Heart Failure: a Review of the Evidence

    Article • Current Atherosclerosis Reports, July 2019, Springer Science + Business Media

    Dr Matthew M Y Lee

  88. Poster Session - Poster session 2

    Article • European Heart Journal - Cardiovascular Imaging, January 2019, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  89. Diabetic cardiomyopathy

    Article • Heart, October 2018, BMJ

    Dr Matthew M Y Lee

  90. Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial

    Article • European Journal of Heart Failure, May 2018, Wiley

    Dr Matthew M Y Lee

  91. NON-INVASIVE VERSUS INVASIVE MANAGEMENT IN PATIENTS WITH PRIOR CORONARY ARTERY BYPASS SURGERY WITH A NON-ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME: COMPARISONS BETWEEN THE RANDOMIZED CONTROLLED PILOT TRIAL AND REGISTRY

    Article • Journal of the American College of Cardiology, March 2018, Elsevier

    Dr Matthew M Y Lee

  92. 9 Routine non-invasive vs invasive management in patients with prior CABG with a NSTE-ACS: a randomised controlled trial

    Article • January 2018, BMJ

    Dr Matthew M Y Lee

  93. ST and T-Wave Abnormality as Footprint of Myocardial Oedema in Non–ST-Elevation Myocardial Infarction

    Article • Heart Lung and Circulation, January 2018, Elsevier

    Dr Matthew M Y Lee

  94. Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes

    Article • Cardiovascular Drugs and Therapy, September 2017, Springer Science + Business Media

    Dr Matthew M Y Lee

  95. Diagnostic Accuracy of 3.0‐T Magnetic Resonance T1 and T2 Mapping and T2‐Weighted Dark‐Blood Imaging for the Infarct‐Related Coronary Artery in Non–ST‐Segment Elevation Myocardial Infarction

    Article • Journal of the American Heart Association, March 2017, Wolters Kluwer Health

    Dr Matthew M Y Lee

  96. DECISION MAKING USING FRACTIONAL FLOW RESERVE IS ASSOCIATED WITH LOWER RATES OF INCOMPLETE REVASCULARIZATION COMPARED WITH ANGIOGRAPHIC GUIDED DECISION MAKING AMONGST PATIENTS WITH NSTEMI

    Article • Journal of the American College of Cardiology, March 2017, Elsevier

    Dr Matthew M Y Lee

  97. Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS)

    Article • Open Heart, April 2016, BMJ

    Dr Matthew M Y Lee

  98. Assessment of Fractional Flow Reserve in Patients With Recent Non–ST-Segment–Elevation Myocardial Infarction

    Article • Circulation Cardiovascular Interventions, August 2015, Wolters Kluwer Health

    Dr Matthew M Y Lee

  99. Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial

    Article • European Heart Journal, September 2014, European Society of Cardiology

    Dr Matthew M Y Lee

  100. Adenosine

    Article • JACC Cardiovascular Interventions, June 2014, Elsevier

    Dr Matthew M Y Lee

  101. 21 * MANAGEMENT OF RECURRENT URINARY TRACT INFECTIONS IN ELDERLY INPATIENTS

    Article • Age and Ageing, June 2014, Oxford University Press (OUP)

    Dr Matthew M Y Lee

  102. 79 Diagnostic Accuracy of Myocardial Fractional Flow Reserve for Reversible Perfusion Abnormalities in Patients with Recent Non-ST Elevation Myocardial Infarction

    Article • Heart, May 2014, BMJ

    Dr Matthew M Y Lee

  103. 38 T1 and T2 Mapping Have Higher Diagnostic Accuracy for the Ischaemic Area-at-risk in Nstemi Patients Compared with Dark Blood Imaging

    Article • Heart, May 2014, BMJ

    Dr Matthew M Y Lee

  104. Thrombus Aspiration during Myocardial Infarction

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2014, New England Journal of Medicine (NEJM/MMS)

    Dr Matthew M Y Lee

  105. Cardiac magnetic resonance imaging: the new reference method for infarct characterization and prognostication after myocardial infarction?

    Article • European Heart Journal - Cardiovascular Imaging, November 2013, European Society of Cardiology

    Dr Matthew M Y Lee

  106. TCT-84 Fractional Flow Reserve versus Angiography in Guiding Management to Optimize Outcomes in Non-ST Elevation Myocardial Infarction (FAMOUS - NSTEMI) Clinical Trial: Study Design and Baseline Characteristics of Randomized Participants.

    Article • Journal of the American College of Cardiology, October 2013, Elsevier

    Dr Matthew M Y Lee

  107. TCT-82 Fractional Flow Reserve versus Angiography in Guiding Management to Optimize Outcomes in Non-ST Elevation Myocardial Infarction (FAMOUS - NSTEMI) Clinical Trial: Relationships Between FFR and Angiographic Stenosis Severity at Baseline.

    Article • Journal of the American College of Cardiology, October 2013, Elsevier

    Dr Matthew M Y Lee

  108. Reducing Personal Exposure to Particulate Air Pollution Improves Cardiovascular Health in Patients with Coronary Heart Disease

    Article • Environmental Health Perspectives, January 2012, Environmental Health Perspectives

    Dr Matthew M Y Lee

  109. 051 Reducing particulate air pollution exposure in patients with coronary heart disease: improved cardiovascular health

    Article • Heart, June 2010, BMJ

    Dr Matthew M Y Lee